Weiquan Zhu, PhD

Languages

  • Chinese
  • English

Academic Information

  • Departments: Internal Medicine - Research Assistant Professor, Pathology - Adjunct Instructor
  • Divisions: Cardiovascular Medicine, Microbiology and Immunology

Academic Office Information

  • 801-585-0869
  • 360 Wakara Way
    Molecular Medicine Program, University of Utah
    360 WAKARA WAY, Room: 4110A
    SALT LAKE CITY, UT 84108

Email: weiquan.zhu@u2m2.utah.edu

Education History

Type School Degree
Fellowship University of Utah
Molecular Medicine
Postdoctoral Fellow
Doctoral Training Chinese Academy of Medical Sciences & Peking Union Medical College
Molecular Biology and Biochemistry
Ph.D.
Graduate Training Nanjing Normal University
Molecular Zoology
M.S.
Undergraduate Yancheng Normal College
Biology
B.S.

Global Impact

Education History

Type School Degree Country
Doctoral Training Chinese Academy of Medical Sciences & Peking Union Medical College
Molecular Biology and Biochemistry
Ph.D. China
Graduate Training Nanjing Normal University
Molecular Zoology
M.S. China
Undergraduate Yancheng Normal College
Biology
B.S. China

Awards & Honors

Description Country
Beijing Science and Technology Award,1st prize, Application of stem cell transplantation in the treatment of ischemic heart disease China
Excellent Achievement Award for Scientific Research in Colleges and Universities, 2nd prize. Mechanism and Intervention Strategies of Low Survival of Stem Cells Induced by Myocardial Ischemic Microenvironment China

Selected Publications

Journal Article

  1. Gibson CC, Davis CT, Zhu W, Bowman-Kirigin JA, Walker AE, Tai Z, Thomas KR, Donato AJ, Lesniewski LA, Li DY (2015). Dietary Vitamin D and Its Metabolites Non-Genomically Stabilize the Ensothelium. PLoS One, 10(10).
  2. Gibson CC, Zhu W, Davis CT, Bowman-Kirigin JA, Chan AC, Ling J, Walker AE, Goitre L, Delle Monache S, Retta SF, Shiu YT, Grossmann AH, Thomas KR, Donato AJ, Lesniewski LA, Whitehead KJ, Li DY (2015). Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation, 131(3), 289-99.
  3. Davis CT, Zhu W, Gibson CC, Bowman-Kirigin JA, Sorensen L, Ling J, Sun H, Navankasattusas S, Li DY (2014). ARF6 inhibition stabilizes the vasculature and enhances survival during endotoxic shock. J Immunol, 192(12), 6045-52.
  4. Yu J, Zhang X, Kuzontkoski PM, Jiang S, Zhu W, Li DY, Groopman JE (2014). Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway. Cell Commun Signal, 12, 25.
  5. Sawada J, Urakami T, Li F, Urakami A, Zhu W, Fukuda M, Li DY, Ruoslahti E, Komatsu M (2012). Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell, 22(2), 235-49.
  6. Prasad A, Kuzontkoski PM, Shrivastava A, Zhu W, Li DY, Groopman JE (2012). Slit2N/Robo1 inhibit HIV-gp120-induced migration and podosome formation in immature dendritic cells by sequestering LSP1 and WASp. PLoS One, 7(10), e48854.
  7. Zhang X, Yu J, Kuzontkoski PM, Zhu W, Li DY, Groopman JE (2012). Slit2/Robo4 signaling modulates HIV-1 gp120-induced lymphatic hyperpermeability. PLoS Pathog, 8(1), e1002461.
  8. London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY (2010). Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med, 2(23), 23ra19.
  9. Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, Lim CJ, Chen H, Zhang Q, Schultz PG, Hayallah AM, Thomas KR, Famulok M, Zhang K, Ginsberg MH, Li DY (2009). Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol, 11(11), 1325-31.
  10. Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, Mayo AH, Drakos SG, Jones CA, Zhu W, Marchuk DA, Davis GE, Li DY (2009). The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med, 15(2), 177-84.
  11. Chen J, Chen Y, Zhu W, Han Y, Han B, Xu R, Deng L, Cai Y, Cong X, Yang Y, Hu S, Chen X (2008). Specific LPA receptor subtype mediation of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NFkappaB signal pathways. J Cell Biochem, 103(6), 1718-31.
  12. Chen J, Baydoun AR, Xu R, Deng L, Liu X, Zhu W, Shi L, Cong X, Hu S, Chen X (2008). Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Stem Cells, 26(1), 135-45.
  13. Chen J, Han Y, Zhu W, Ma R, Han B, Cong X, Hu S, Chen X (2006). Specific receptor subtype mediation of LPA-induced dual effects in cardiac fibroblasts. FEBS Lett, 580(19), 4737-45.
  14. Wang Y, Chen X, Zhu W, Zhang H, Hu S, Cong X (2006). Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol, 33(8), 696-701.
  15. Zhu W, Chen J, Cong X, Hu S, Chen X (2006). Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells, 24(2), 416-25.
  16. Yiquan Wang, Zhu W, Lei Huang, et al (2006). Genetic diversity of Chinese alligator (Alligator sinensis) revealed by AFLP analysis: an implication on the management. Biodivers Conserv, 2945-55.
  17. Zhu W, Chen Xi, Cong Xiangfeng (2004). MSCs undergo apoptosis in a model of ischemia consisting of hypoxia and serum deprivation. (19), 352.

Patent

  1. Dean Li, Nyall London, Weiquan Zhu (2012). COMPOSITIONS AND METHODS FOR PROMOTING VASCULAR BARRIER FUNCTION AND TREATING PULONARY FIBROSIS. U.S. Patent No. US20120129757 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Dean Y. Li, Nyall London, Weiquan Zhu (2010). Compositions and methods for promoting vascular barrier function and treating pulmonary fibrosis. U.S. Patent No. US20120129757 A1. Washington, D.C.:U.S. Patent and Trademark Office.